Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection

AIDS

Volumn 21, Issue 1, 2007, Pages 71-76

  Cooper, Curtis L ^a   Mills, Edward ^a   Angel, Jonathan B ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

HAART; Hepatitis C virus; HIV; Lipids

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; INTERFERON; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPID ANALYSIS; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; HYPERLIPIDEMIAS; INTERFERONS; MALE; MIDDLE AGED;

EID: 33845477478     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3280110ada     Document Type: Article

References (35)

1. Sherman KE, Roustrer S, Chung R, Rajicic N. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antivir Ther 2000; 5 (Suppl. 1):64-65.
2. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345:41-52.
3. Cooper C, Cameron DW. Effect of alcohol use and highly active antiretroviral therapy on plasma levels of hepatitis C virus (HCV) in patients coinfected with HIV and HCV. Clin Infect Dis 2005; 41 (Suppl. 1):S105-S109.
4. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
5. Qurishi N, Kreuzberg C, Luchters G, Effenberger W, Kupfer B, Sauerbruch T, et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003; 362:1708-1713.
6. Greub G, Ledergerber B, Battegay M, Grob P, Perrin L, Furrer H, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
7. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288:199-206.
8. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-450.
9. Laguno M, Murillas J, Blanco JL, Martinez E, Miquel R, Sanchez-Tapias JM, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18:F27-F36.
10. Polgreen PM, Fultz SL, Justice AC, Wagner JH, Diekema DJ, Rabeneck L, et al. Association of hypocholesterolaemia with hepatitis C virus infection in HIV-infected people. HIV Med 2004; 5:144-150.
11. Maggi G, Bottelli R, Gola D, Perricone G, Posca M, Zavaglia C, et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996; 28:436-440.
12. Stapleton JT, Swindells S, Polgreen PM. Hepatitis C virus infection is associated with a decreased risk of hypercholesterolemia but not hyperglycemia in HIV-infected people. In: XIVth International AIDS Conference. Barcelona, 7-12 July 2002 [Abstract ThPeC7517].
13. Zoli M, Cordianai M, Marchesini G, Iervese T, Labate AM, Bonazzi C, et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol 1991; 86:1508-1513.
14. D'Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 1998; 33:1213-1218.
15. Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-1074.
16. Friis-Moller N, Reiss P, El-Sadr W, D'Armino Monforte A, Thiebaut R, de Wit S, et al. Exposure to PI and NNRTI and risk of myocardial infarction: results from the D:A:D: Study. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006 [Abstract 144].
17. Currie J, Kendall M, Henry K, Torriani FJ, Conley J, Alston-Smith B, et al. 3-Year follow-up of carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. In: 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, USA, 5-8 February 2006 [Abstract 145].
18. Hamamoto S, Uchida Y, Wada T, Moritani M, Sato S, Hamamoto N, et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 2005; 20:204-208.
19. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003; 38:75-85.
20. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993; 67:1953-1958.
21. Xiang J, Klinzman D, McLinden J, Schmidt WN, LaBrecque DR, Gish R, et al. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 1998; 72:2738-2744.
22. Prince AM, Huima-Byron T, Parker TS, Levine M. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepat 1996; 3:11-17.
23. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med Microbiol Immunol (Berl) 1992; 181:293-300.
24. Monazahian M, Kippenberger S, Muller A, Seitz H, Bohme I, Grethe S, et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol (Berl) 2000; 188:177-184.
25. Wunschmann S, Muller HM, Stipp CS, Hemler ME, Stapleton JT. Hepatitis C virus (HCV) E2 protein interactions with human lipoproteins. Enhanced binding of HCV E2 and lipoproteins to cells requires both human CD81 and the human LDL receptor. In: XIVth International AIDS Conference. Barcelona, 7-12 July 2002 [Abstract WePeB6041].
26. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J Virol 2000; 74:10055-10062.
27. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M, et al. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002; 76:6919-6928.
28. Hope RG, Murphy DJ, McLauchlan J. The domains required to direct core proteins of hepatitis C virus and GB virus-B to lipid droplets share common features with plant oleosin proteins. J Biol Chem 2002; 277:4261-4270.
29. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
30. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S, et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999; 57:223-229.
31. Agnello V, Abel G, Elfahal M, Knight GB, Zhang QX. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 1999; 96:12766-12771.
32. Voisset C, Callens N, Blanchard E, Op De Beeck A, Dubuisson J, Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J Biol Chem 2005; 280:7793-7799.
33. Hofer H, Bankl HC, Wrba F, Steindl-Munda P, Peck-Radosavljevic M, Osterreicher C, et al. Hepatocellular fat accumulation and low serum cholesterol in patients infected with HCV-3a. Am J Gastroenterol 2002; 97:2880-2885.
34. Barba G, Harper F, Harada T, Kohara M, Goulinet S, Matsuura Y, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 1997; 94:1200-1205.
35. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001; 34:428-434.